Article
A yeast-based system to study SARS-CoV-2 Mpro structure and to identify nirmatrelvir resistant mutations.
PLoS pathogens - 1 Aug 2023
Ou Jin, Lewandowski Eric M, Hu Yanmei, Lipinski Austin A, Aljasser Ali, Colon-Ascanio Mariliz, Morgan Ryan T, Jacobs Lian M C, Zhang Xiujun, Bikowitz Melissa J, Langlais Paul R, Tan Haozhou, Wang Jun, Chen Yu, Choy John S
Abstract excerpt
The SARS-CoV-2 main protease (Mpro) is a major therapeutic target. The Mpro inhibitor, nirmatrelvir, is the antiviral component of Paxlovid, an orally available treatment for COVID-19. As Mpro inhibitor use increases, drug resistant mutations will likely emerge. We have established a non-pathogenic system, in which yeast growth serves as an approximation for Mpro activity, enabling rapid identification of mutants...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.